Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

Identification

Summary

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

Brand Names

Menveo

Generic Name

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

DrugBank Accession Number

DB10061

Background

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria Neisseria meningitidis entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.¹ Several serogroups of N. meningitidis - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.¹ Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains serogroup A, C, Y, and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein carrier, resulting in four drug substances contained in each dose of vaccine.²

Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.²

Type

Biotech

Groups

Approved

Biologic Classification

Vaccines
Other vaccines

Synonyms

Not Available

Pharmacology

Indication

This is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine does not prevent N. meningitidis serogroup B infections.²

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup A
• Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup C
• Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup W-135
• Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup Y

Associated Therapies

• Meningococcal Immunisation

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine that works to potentiate immune response against Neisseria meningitidis serogroups A, C, Y, and W-135 in vaccinated individuals.²

Mechanism of action

Neisseria meningitidis is a human-encapsulated Gram-negative diplococcus that is known to cause serious and life-threatening invasive disease. N. meningitidis has several different serogroups that are classified based on the composition of capsular polysaccharide (CPS) polymers. Among the serogroups, serogroups A, B, C, W, Y, and X account for the majority of meningococcal diseases.¹

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains bacterial CPS (serogroup A, C, Y, and W-135 oligosaccharides) conjugated to a carrier protein (CRM₁₉₇), allowing more robust antibody responses compared to plain polysaccharide vaccines.¹ Upon administration, this conjugate vaccine promotes the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135 in vaccinated individuals.²

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abatacept	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Abatacept.
Adalimumab	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Adalimumab.
Alclometasone	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alclometasone.
Aldesleukin	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Aldesleukin.
Alefacept	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alefacept.
Alemtuzumab	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alemtuzumab.
Altretamine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Altretamine.
Amcinonide	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Amcinonide.
Amsacrine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Amsacrine.
Anakinra	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Anakinra.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Menjugate Liquid	Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (25 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (10 mcg/0.5mL)	Suspension	Intramuscular	Glaxosmithkline Inc	2015-10-07	Not applicable
Menveo	Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)	Powder, for solution; Solution	Intramuscular	Glaxosmithkline Inc	2010-07-29	Not applicable

Categories

Drug Categories

• Diphtheria Vaccines
• Meningococcal Vaccines
• Vaccines

Classification

Not classified

Affected organisms

• Neisseria meningitidis

Chemical Identifiers

UNII

Not Available

CAS number

Not Available

References

General References

1. Daraghma R, Sapra A: Meningococcal Vaccine . [Article]
2. FDA Approved Drug Products: MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] solution for injection, for intramuscular use [Link]

External Links

Not Available

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Papilloma Viral Infection	1
4	Completed	Basic Science	Meningitis / Meningococcal Disease / Septicemia	1
4	Completed	Other	Meningococcal Meningitis	1
4	Completed	Prevention	Meningococcal Disease	1
4	Completed	Prevention	Meningococcal Disease, Invasive	1
4	Completed	Treatment	Immunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis	1
4	Recruiting	Prevention	Human Immunodeficiency Virus (HIV) Infections / Meningococcal Infections / Pneumococcal Infection	1
3	Active Not Recruiting	Prevention	Meningococcal Infections	1
3	Completed	Prevention	Meningitis / Septicemia	1
3	Completed	Prevention	Meningococcal Infections	3

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Suspension	Intramuscular
Powder, for solution; solution	Intramuscular

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at November 30, 2015 21:23 / Updated at November 01, 2022 19:17